Rong Guo, MD
Internal Medicine · Phoenix, AZNPI 1104211705
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Pharmacosmos Therapeutics Inc. accounts for 81.7% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2022 at $16,750 and has fallen 97.4% since, to $443 in 2025. Among internal medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 141 payments — averaging $142.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacosmos Therapeutics Inc.$16K
- Medtronic$1K
- Insulet Corporation$413
- Novo Nordisk$342
- Cequr Corporation$291
- Corcept Therapeutics$278
- plus $1K from 16 others
What the payments were for
- Consulting fees$4462%
- Speaking & faculty fees$6,00030%
- Travel & lodging$10,27751%
- Food & beverage$3,32917%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacosmos Therapeutics Inc. | 13 | $16,414 |
| Medtronic(2 entities) | 19 | $1,106 |
| Insulet Corporation | 25 | $413 |
| Novo Nordisk | 21 | $342 |
| Cequr Corporation | 1 | $291 |
| Corcept Therapeutics | 4 | $278 |
| AstraZeneca | 10 | $259 |
| Boehringer Ingelheim | 11 | $257 |
| Amgen(2 entities) | 4 | $180 |
| Lilly USA, LLC | 9 | $163 |
| Sanofi-aventis U.S. LLC | 6 | $90 |
| Abbott | 3 | $51 |
| Shire North American Group Inc | 3 | $50 |
| Bayer | 3 | $48 |
| Radius Health, Inc. | 2 | $32 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Merck | 1 | $15 |
| Mannkind Corporation | 1 | $15 |
| Vivus LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monoferric$16,245
- Minimed 670G System$670
- CeQur Simplicity$291
- Korlym$249
- FARXIGA$125
- EVENITY$122
- Minimed 530G$119
How this compares
$20,091 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 242 | $310,139 |
| JardianceEmpagliflozin | 263 | $266,270 |
| TrulicityDulaglutide | 220 | $260,707 |
| MounjaroTirzepatide | 152 | $204,003 |
| FarxigaDapagliflozin Propanediol | 152 | $128,180 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 24 | $48,347 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 52 | $38,094 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $23,370 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $21,858 |
| Humalog Kwikpen U-200Insulin Lispro | 13 | $17,601 |
| Humalog Kwikpen U-100Insulin Lispro | 59 | $14,422 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $11,850 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 96 | $11,664 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 78 | $11,129 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $8,553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $163 | $470,090409 claims |
| Novo NordiskOzempic, Novolog | $342 | $314,970264 claims |
| Boehringer IngelheimJardiance | $257 | $266,270263 claims |
| AstraZenecaFarxiga | $259 | $128,180152 claims |
| Sanofi-aventis U.S. LLCLantus | $90 | $2,38211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Phoenix
- Frank LovecchioPhoenix$911K
- Nasser HajaigPhoenix$687K
- Kelly KrohnPhoenix$262K
- Paul StanderPhoenix$222K
- Howard GrossmanPhoenix$131K
- Nafis Shamsid-DeenPhoenix$115K
- Shishir MurarkaPhoenix$79K
- Mark WongPhoenix$71K
- Geoffrey OrmePhoenix$27K
- Roberto RuizPhoenix$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.